aTyr Pharma (NASDAQ:LIFE – Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01, Yahoo Finance reports. The firm had revenue of $0.24 million during the quarter, compared to analyst estimates of $0.11 million. aTyr Pharma […]
aTyr Pharma, Inc. (NASDAQ:LIFE – Get Free Report) was the recipient of a significant increase in short interest in March. As of March 15th, there was short interest totalling 289,300 shares, an increase of 167.4% from the February 29th total of 108,200 shares. Based on an average daily volume of 521,200 shares, the short-interest ratio […]
HC Wainwright reissued their buy rating on shares of aTyr Pharma (NASDAQ:LIFE – Free Report) in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has a $35.00 price target on the biotechnology company’s stock. Separately, StockNews.com lowered aTyr Pharma from a hold rating to a sell rating in a research […]
Pale Fire Capital SE purchased a new position in shares of aTyr Pharma, Inc. (NASDAQ:LIFE – Free Report) during the third quarter, Holdings Channel reports. The fund purchased 55,857 shares of the biotechnology company’s stock, valued at approximately $88,000. A number of other large investors also recently added to or reduced their stakes in the […]
Pale Fire Capital SE bought a new stake in aTyr Pharma, Inc. (NASDAQ:LIFE – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 55,857 shares of the biotechnology company’s stock, valued at approximately $88,000. Pale Fire Capital […]